• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    PCI Pharma Services

    Adare Pharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Alcami

    Adare Pharma Solutions

    PCI Pharma Services

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Preclinical Planning for Successful Drug Development

    When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.

    Preclinical Planning for Successful Drug Development
    Related CONTENT
    • ERS Genomics Appoints IP & Commercial Development VP
    • Vectura and Monash University Support Development of Inhaled Oxytocin
    • Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach
    • Embedding your Drug Strategy Within a Solid Foundation for Success
    • Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance
    Mingyi Trimble, WuXi AppTec09.09.20
    In the pharmaceutical and biotechnology industry, time really is money. Drug developers often feel the consistent pressure of demanding deadlines as the race to submission closes in. During the preclinical testing and development phases, some of the main stressors that drug developers encounter are primarily linked to timelines, either set in place by the company’s leadership, investors or a regulatory body. The question is, what can drug developers do to alleviate timeline stressors?

    Exploring why timelines weigh so heavily on drug developers, how to evaluate preclinical testing deadlines and insight on the industry’s best practices can set drug developers up for success on their next program. Drug development companies that use timeline projections to their advantage and apply timesaving techniques can often reduce the amount of pressure felt throughout this process.

    Pressure points for drug developers
    It is no industry secret that testing and regulatory submission deadlines constitute a significant source of stress for drug development companies, and this strain can stem from a multitude of factors.

    Smaller drug development companies may have comparatively limited resources that can make the research and development (R&D), along with the regulatory required testing processes, more demanding and arduous. Lean staffing can lead to specific knowledge gaps, despite any niche expertise represented on the team. For example, a drug development company may have an incredible R&D biologist but may not have a team member as well-versed in the intricacies of Investigational New Drug (IND) enabling toxicology testing. This company makeup can make planning for regulatory required testing and data compilation more difficult, and potentially threaten the success of the compound.

    Additionally, smaller drug development companies have an increased obligation to fundraise and must keep constant tabs on the financial burn-rate. While necessary, it can lead to an imbalance in other sectors of the business and contribute to delays. Make sure enough time is constituted to fundraising efforts while still leaving space for traditional development work. It is easy to overlook the fundraising time commitment and how this will interfere with development timelines.

    Larger drug development companies, on the other hand, often trace timeline pressure back to the regulatory filing deadline. Large drug development companies are working against a target date to complete preclinical studies, analyze data and compile an application. Many larger drug developers feel the clock ticking as soon as they receive the program, which acts as both a motivational force as well as a constant stressor to become the first to have an approved drug with a filed patent.

    Acknowledging stressors and their origins helps drug developers plan for timeline restrictions and accuracies. Whether developers are small, large or in between, appropriate planning can make sure timelines are achievable, and no gaps are left unaddressed.

    The art of planning
    Comprehensive and steady planning protects progress and keeps programs on track. The most successful drug development companies are continually overseeing their testing to ensure it aligns with their planned timelines and adjusting schedules as necessary. To do this, drug developers need to acknowledge the key considerations—testing objectives, potential obstacles and regulatory obligations—when evaluating preclinical testing timelines.

    Drug developers should start planning with the end goal of their program in mind when creating accurate and reasonable timelines, which in many cases is a successful IND filing. By working backward from this goal, timelines become more precise and detailed. Additionally, it is easier to find planning gaps where the deadline is unrealistic for the testing and the necessary amount of work at hand.

    To set themselves up for the best chance at success, drug developers should create or review this timeline with an outside source, such as a consultant or laboratory testing partner, for accuracy. These sources can confirm the palpability of the schedule and point out any missed steps.

    A pragmatic approach that drug developers should implement is clinical trial planning before preclinical work even begins. The in vivo and in vitro preclinical testing design needs to support the planned First in Human (FIH) trial. Therefore, the clinical trial plans need a certain level of foresight. One example is the intended dose route and frequencies; if the drug is to be administered via intravenous infusion once a week, it is essential to include proper infusion duration and frequencies for the appropriate preclinical test systems.

    When it comes to the study design, there is not a one-size-fits-all approach and drug developers cannot lean on a list of standard studies for sufficient submissions. Instead, customizing testing to the specific drug and the intended population is necessary for approval from regulatory agencies. A small molecule anti-microbial drug, for instance, requires a different testing strategy than an immuno-oncology product because determining the safety and efficacy of the two compounds will require different regulatory plans. Planning these processes thoroughly and continuously monitoring will help narrow down more realistic timelines for testing and submission.

    When done correctly, Gantt charts can act as a guide to reference for the next steps in the program’s evolution. Using them like this reduces the stress ordinarily associated with timelines and, instead, turns them into a tool.

    Regulatory realities
    With the preclinical goal of successfully filing regulatory submissions, drug developers can look upon regulatory requirements for options to alleviate timeline stress.

    Drug developers should view regulatory agencies as a partner, rather than perceiving them as another hurdle to set them back. Regulators can offer insight into the strength of a drug development plan, what it may be missing and raise questions or concerns that a drug developer can address in studies and submission packages. Thus, before testing begins, drug developers have an opportunity to correct any design flaws that could have put the submission at risk. Ultimately, building relationships and having productive meetings with regulators can help with the structure, organization and pragmatism of a drug development timeline.

    Drug developers can also use common regulatory practices for a timeline advantage. One often-overlooked timesaving technique is dual filing, meaning filing under two or more regulatory bodies to access various markets simultaneously. There are many scenarios where dual filing makes the most sense financially and from a timeline perspective. If a drug developer is planning to file with the U.S. Food and Drug Administration (FDA) now, and China’s National Medical Products Administration (NMPA) soon after, it may be best to file dually to avoid the need to duplicate studies. Drug developers should weigh their options and proceed with the most cost-effective approach. With the proper planning and foresight, this approach could significantly affect submission timing by advancing into markets earlier and utilizing fewer preclinical studies while avoiding duplications.

    Advice on timesaving techniques
    Understanding strategies that can mitigate the strain of disrupted timelines can significantly support the preclinical testing process and move projects forward more efficiently. Recognize these industry best practices as a helpful start:

    1. Contact a testing partner early. Vetting testing laboratories is a time-consuming process. By anticipating testing needs and beginning the process early, drug developers can minimize the chances of delays. Many drug developers vet multiple testing laboratories to get a full snapshot of available options and price ranges. Moreover, with the restrictions from the COVID-19 pandemic, many testing laboratories are offering virtual audits for those vetting them. Even if a drug developer decides not to outsource testing to a particular testing laboratory immediately, it is important to create relationships with professionals in the testing space, which can pay dividends downstream.

    2. Ensure vendor capacity and flexibility. When a drug developer has identified a testing laboratory, it is critical to confirm their capacity. If a testing laboratory doesn’t have the space, staff and resources or time to conduct the studies, it can send the drug developer back to the drawing board to find another laboratory testing partner. Currently, many testing laboratories have limited staff, laboratory space, or access to a specific animal model, making it essential to check in with them about lead time and capacity. Drug developers need to be cognizant of the current gap in the industry and acknowledge how it may affect their timelines. Work with the testing laboratories to ensure they are as committed to the compound as the drug developer is.

    3. Send enough test article—and on time. If the testing laboratory receives an insufficient amount of test material, studies can’t begin as planned. Proper communication between the testing laboratory and the drug developer can help to avoid such delays. A testing laboratory can aid the drug developer in accurately predicting the necessary amount of test articles with required studies in mind. While the cost and availability of these articles can prompt drug developers to send them conservatively, the expense of resulting delays is usually much more significant. Additionally, drug developers need to account for international shipping and other obstacles to ensure that the testing laboratory receives the test article on time for testing to begin. It is common for laboratories to have advice and procedures on these timing requirements, so be sure to check in with them.

    4. Streamline communication. Miscommunication is one of the largest contributors to timeline setbacks during preclinical testing. These setbacks can occur more frequently with a high number of testing laboratories who do not directly communicate with each other. Details can be lost or omitted when a single person is relaying communication between laboratories and other stakeholders, which can then affect the testing and submission timelines. For instance, if an unexpected metabolite is observed during metabolism testing or if a unique impurity is uncovered during the synthetic process, and the testing laboratory fails to obtain this information, studies could be delayed as the toxicologist works on the possible study design modifications. This miscommunication can prompt delays and sizeable cost inefficiencies. Consolidating testing to one or two testing laboratories can streamline communication and the preclinical processes, while also providing regulatory and clinical insight.

    5. Anticipate the surprises. Although it is difficult to know how to prepare for unintended findings during preclinical testing, drug developers should do everything in their power to ready themselves and their partners for potential obstacles. Drug development companies can alleviate strain and dial down the severity of unexpected setbacks by building time into the overall testing timeline. When surprises do occur during development, ensure that the testing laboratory partner has the flexibility to reschedule studies and troubleshoot. This becomes essential when a drug developer needs to perform an additional investigative study as a consequence of an unanticipated surprise. If a laboratory testing partner can’t schedule the new study until later, the drug developer’s timeline is significantly elongated. To be prepared, drug development companies should fully understand the delay, cancellation and rescheduling policies and capabilities of all testing laboratory partners. Drug developers that are aware of these contractual policies can better prepare for when surprises occur and can develop and execute on the next steps.

    Drug developers can alleviate stress when they start to use timelines as a tool for their program’s guidance, rather than a consistent barrier. Identifying strategies to consolidate inefficiencies or dissolve burdens will streamline the drug development process.

    Be sure to review the industry’s best practices when it comes to creating and calculating a program’s timeline. Consulting a testing partner early on, sending a sufficient amount of test articles, avoiding miscommunication, securing capacity and forecasting surprises are all essential features to assess.

    It’s true that unanticipated findings and testing surprises will always be a part of drug development, and learning how to handle and solve these issues can support preparedness and make the day-to-day work that much more rewarding. 


    Mingyi Trimble, ScD, DABT, is Senior Technical Director of Toxicology at WuXi AppTec Laboratory Testing Division. Dr. Trimble has over 15 years of preclinical development experience and is an expert in regulatory drug development for a wide range of therapeutic products and indications. After receiving her Doctor of Science degree in Toxicology and MS in Regulatory Toxicology and Risk Assessment from Tulane University in New Orleans, she began her career in the contract research organization (CRO) industry. In her current position as WuXi AppTec’s Senior Technical Director, Dr. Trimble provides technical and scientific support, enhancing WuXi AppTec’s ability to handle technical questions with a quicker response rate for our clients. Dr. Trimble is currently a Diplomate of the American Board of Toxicology since 2005 and she is an active member of the Society of Toxicology (SOT), American College of Toxicology (ACT), American Society of Gene and Cell Therapy (ASGCT), SOT Northern California Regional Chapter and SOT American Association of Chinese in Toxicology.
    Related Searches
    • Drug Development
    • Preclinical Outsourcing
    Suggested For You
    ERS Genomics Appoints IP & Commercial Development VP ERS Genomics Appoints IP & Commercial Development VP
    Vectura and Monash University Support Development of Inhaled Oxytocin Vectura and Monash University Support Development of Inhaled Oxytocin
    Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach
    Embedding your Drug Strategy Within a Solid Foundation for Success Embedding your Drug Strategy Within a Solid Foundation for Success
    Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance Drug Safety and Pharmacovigilance: Effective Drug Safety Reporting and Surveillance
    Evotec and Novo Nordisk Form Strategic Alliance Evotec and Novo Nordisk Form Strategic Alliance
    RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership
    Avacta Appoints Chief Development Officer Avacta Appoints Chief Development Officer
    CoreRx Fully Operational in New Product Development Center CoreRx Fully Operational in New Product Development Center
    Avid Selected to Lead Process Development of IOV-3001 Avid Selected to Lead Process Development of IOV-3001
    Samsung Biologics Launches S-CHOice Samsung Biologics Launches S-CHOice
    EU Compassionate Use Programs - Where’s My Drug? EU Compassionate Use Programs - Where’s My Drug?
    Orion Biotechnology Receives Funding to Develop OB-002 Orion Biotechnology Receives Funding to Develop OB-002
    Introduction to PCI Drug Development and Manufacturing Services Introduction to PCI Drug Development and Manufacturing Services
    Jubilant Biosys Merges with Jubilant Chemsys Jubilant Biosys Merges with Jubilant Chemsys

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19

    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19


    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19

    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19


    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Drug Development
      Streamlining Drug Development:

      Streamlining Drug Development:

      Four key takeaways from Veeva’s 2018 R&D Summit
      Henry Levy, General Manager of Vault CDMS, Veeva Systems 11.13.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Trending
    • The Future Of Clinical Trials Series: Part I
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • Nexelis Acquires GSK Vax Lab In Marburg
    • CDMO Northway Biotech Expands In U.S.
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login